Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Nov 15;11(1):22267.
doi: 10.1038/s41598-021-01708-2.

Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial

Can Cui #  1 , Xiujuan Li #  1 , Yong Lyu  1 , Li Wei  1 , Bingxin Zhao  1 , Shiao Yu  1 , Junbo Rong  1 , Yanhui Bai  1 , Aicun Fu  2
Affiliations
Randomized Controlled Trial

Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial

Can Cui et al. Sci Rep. .

Abstract

Four hundred myopic children randomly received atropine 0.02% (n = 138) or 0.01% (n = 142) in both eyes once-nightly or only wore single-vision spectacles (control group) (n = 120) for 2 years. Spherical equivalent refractive error (SER), axial length (AL), pupil diameter (PD), and amplitude of accommodation (AMP) were measured every 4 months. After 2 years, the SER changes were - 0.80 (0.52) D, - 0.93 (0.59) D and - 1.33 (0.72) D and the AL changes were 0.62 (0.29) mm, 0.72 (0.31) mm and 0.88 (0.35) mm in the 0.02% and 0.01% atropine groups and control group, respectively. There were significant differences between changes in SER and AL in the three groups (all P < 0.001). The changes in SER and AL in the 2nd year were similar to the changes in the 1st year in the three groups (all P > 0.05). From baseline to 2 years, the overall decrease in AMP and increase in PD were not significantly different in the two atropine groups, whereas the AMP and PD in the control group remained stable (all P > 0.05). 0.02% atropine had a better effect on myopia control than 0.01% atropine, and its effects on PD and AMP were similar to 0.01% atropine. 0.02% or 0.01% atropine controlled myopia progression and AL elongation synchronously and had similar effects on myopia control each year.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Subject recruitment and randomization flowchart.
Figure 2
Figure 2
Measurement of spherical equivalent refractive error and axial length over time.
Figure 3
Figure 3
Measurement of pupil diameter and accommodation amplitude over time.
See this image and copyright information in PMC

References

    1. Pan CW, Dirani M, Cheng CY, Wong TY, Saw SM. The age-specific prevalence of myopia in Asia: A meta-analysis. Optom. Vis. Sci. 2015;92:258–266. doi: 10.1097/OPX.0000000000000516. - DOI - PubMed
    1. Morgan IG, Ohno-Matsui K, Saw SM. Myopia. Lancet. 2012;379:1739–1748. doi: 10.1016/S0140-6736(12)60272-4. - DOI - PubMed
    1. Lam CS, Lam CH, Cheng SC, Chan LY. Prevalence of myopia among Hong Kong Chinese schoolchildren: changes over two decades. Ophthalmic Physiol. Opt. 2012;32:17–24. doi: 10.1111/j.1475-1313.2011.00886.x. - DOI - PubMed
    1. Holden BA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123:1036–1042. doi: 10.1016/j.ophtha.2016.01.006. - DOI - PubMed
    1. Naidoo KS, et al. Potential lost productivity resulting from the global burden of myopia: Systematic review, meta-analysis, and modeling. Ophthalmology. 2019;126:338–346. doi: 10.1016/j.ophtha.2018.10.029. - DOI - PubMed

Publication types